



Long-Term Follow-Up and Optimization of Interleukin-1 Inhibitors in the Management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort

Véronique Hentgen¹*, Isabelle Koné-Paut², Alexandre Belot³, Caroline Galeotti², Gilles Grateau⁴, Aurelia Carbasse⁵, Anne Pagnier⁶, Pascal Pillet⁷, Marc Delord⁸, Michael Hofer⁹ and Sophie Georgin-Lavialle⁴

OPEN ACCESS

Edited by:

Gerard Bannenberg, Global Organization for EPA and DHA Omega-3s (GOED), United States

Reviewed by:

Luca Cantarini, University of Siena, Italy Selcan Demir, Hacettepe University, Turkey Joost Frenkel, Utrecht University, Netherlands

> *Correspondence: Véronique Hentgen vhentgen@ch-versailles.fr

Specialty section:

This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

Received: 02 June 2020 Accepted: 12 October 2020 Published: 11 January 2021

Citation:

Hentgen V, Koné-Paut I, Belot A, Galeotti C, Grateau G, Carbasse A, Pagnier A, Pillet P, Delord M, Hofer M and Georgin-Lavialle S (2021) Long-Term Follow-Up and Optimization of Interleukin-1 Inhibitors in the Management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort. Front. Pharmacol. 11:568865. doi: 10.3389/fphar.2020.568865 ¹Department of Pediatrics, National Reference Center for Auto-inflammatory Diseases and Amyloidosis, CEREMAIA, Versailles Hospital, Versailles, France, ²Department of Pediatric Rheumatology National Reference Center for Auto-Inflammatory Diseases and Amyloidosis, CEREMAIA, CHU du Kremlin Bicêtre, University of Paris Sud Saclay, UVSQ, Le Kremlin Bicêtre, France, ³Pediatric Nephrology, Rheumatology, Dermatology, HFME, Hospices Civils de Lyon, National Referee Centre RAISE, & INSERM U1111, Université de Lyon, Lyon, France, ⁴Department of Internal Medicine, National Reference Center for Auto-Inflammatory Diseases and Amyloidosis, CEREMAIA, Tenon Hospital, AP-HP, Sorbonne University, Paris, France, ⁵Department of Pediatrics, Hôpital Arnaud de Villeneuve, CHRU Montpellier, Montpellier, France, ⁶Department of Pediatrics, CHU de Grenoble, Grenoble, France, ⁷Department of Pediatrics, Hôpital des Enfants, CHRU Bordeaux, Bordeaux, France, ⁸Direction de La Recherche Clinique et de L'Innovation (DRCI) Versailles Hospital, Versailles, France, ⁹Unité Romande D'Immuno-Rhumatologie Pédiatrique, CHUV, University of Lausanne, Lausanne, Switzerland

Objectives: The major role of interleukin (IL)-1 in the pathogenesis of hereditary recurrent fever syndromes favored the employment of targeted therapies modulating IL-1 signaling. However the best use of IL1 inhibitors in terms of dosage is difficult to define at present.

Methods: In order to better understand the use of IL1 inhibitors in a real-life setting, our study assessed the dosage regimens of French patients with one of the four main hereditary recurrent fever syndromes (Familial Mediterranean Fever (FMF), TNF receptor associated periodic syndrome (TRAPS), cryopyrin associated periodic fever (CAPS) and mevalonate kinase deficiency). The patients were retrieved retrospectively from the JIR cohort, an international platform gathering data of patients with pediatric inflammatory diseases.

Results: Forty five patients of the JIR cohort with a hereditary recurrent fever syndrome had received at least once an IL1 inhibitor (anakinra or canakinumab). Of these, 43% received a lower dosage than the one suggested in the product recommendations, regardless of the type of the IL1 inhibitor. Especially patients with FMF and TRAPS seemed to need lower treatment regimens; in our cohort none of the FMF or TRAPS patients received an intensified dose of IL-inhibitor. On-demand treatment with a short half-life IL-1 inhibitor has also been used successfully for some patients with one of these two conditions The standard dose was given to 42% of the patients; whereas an intensified dose of IL-1 inhibitors was given to 15% of the patients (44% of CAPS patients and 17% of mevalonate kinase deficiency patients). In our cohort each individual patient's need for

1

treatment seemed highly variable, ranging from on demand treatment regimens to intensified dosage maintenance therapies depending on the activity and the severity of the underlying disease.

Conclusion: IL-1 inhibitors are a good treatment option for patients with a hereditary recurrent fever syndrome, but the individual need of the dosage of IL-1 inhibitors to control the disease effectively seems highly variable. Severity, activity but also the type of the underlying disease, belong to the parameters underpinning the treat-to-target strategy implemented in an everyday life practice.

Keywords: anakinra, canakinumab, cryopyrin-associated periodic syndrome, Tumor Necrosis factor (TNF)receptor-associated periodic syndrome, mevalonate kinase deficiency, posology, familial mediterranean fever disease, IL-1 inhibitor

INTRODUCTION

Interleukin (IL)-1 is implicated in the pathogenesis of several systemic auto-inflammatory disorders and this recognition has favored the employment of targeted therapies modulating IL-1 signaling in a wide number of diseases (Cavalli and Dinarello, 2015). Several IL-1 inhibitors have been developed, but in France the marketing authorization has been obtained only for two of them, the IL-1 receptor antagonist analog anakinra and the IL-1 β selective monoclonal antibody canakinumab. The first one was formerly licensed for rheumatoid arthritis, then cryopyrinassociated periodic syndrome (CAPS), and recently in systemic JIA. The second has an indication in the treatment of systemic JIA and in four hereditary systemic auto-inflammatory disorders (European Medicines Agency, 2018b). In 2018, the pivotal placebo-controlled umbrella study with canakinumab has provided the highest level of evidence for the use of IL-1 blockers to control inflammatory symptoms in 3 diseases other than CAPS: i.e. mevalonate kinase deficiency (MKD), TNF receptor associated periodic syndrome (TRAPS), and familial Mediterranean fever (FMF) (De Benedetti et al., 2018). Anakinra will shortly be licensed in France also for colchicine resistant FMF (crFMF) patients (European Medecines Agency, 2018a).

Despite the studies giving short or medium-term results, the use of IL-1 inhibitors on a long term and especially in real life may differ in terms of both intervals between the injections and dosage. Indeed, patients responding insufficiently to IL-1 inhibition, respond completely to a dose increase or shortening of the interval between the doses (Bodar et al., 2011; Grimwood et al., 2015; Kone-Paut et al., 2017; Deshayes et al., 2018). Conversely, the minimum doses required to treat a patient effectively are less well known, considering that the majority of patients are currently treated with a treat-to-target strategy.

In French tertiary care centers, IL-1 inhibitors have been used off-labeled in theses indications for several years (Meinzer et al., 2011; Stankovic et al.,2012; Rossi-Semerano et al., 2015; Abbara et al., 2017). The analysis of these patients therefore presents an unique opportunity to compare the actual doses received by patients in a nation-wide "real-life" setting to the drug dosage recommended in the product recommendations.

MATERIALS AND METHODS

Study Design and Participants

Patients were identified from the JIR cohort, an international multicenter data repository granted by the Swiss-Children-Rheumatisms foundation, which aims to collect both retrospective and prospective information in a variety of juvenile onset systemic inflammatory disorders (http://www.fondationres.org/fr/jircohorte - NTC02377245). For the purpose of the study, only patients from French centers (pediatric and adult) with complete history data and at least one completed follow-up visit were analyzed. Inclusion criteria to the study were all patients.

- 1) with a monogenic autoinflammatory recurrent fever syndrome (CAPS, TRAPS, FMF and MKD) according to the EUROFEVER/Printo classification criteria (Gattorno et al., 2019).
- 2) who received during their follow-up at least one IL-1 inhibitor.

Export of patient's data took place on 12th June 2017, one month before the marketing authorization of canakinumab in France.

Protocol Approvals

This study conformed to the tenets of the Declaration of Helsinki and the protocol was approved by the French Ethic Committee (CCTIRS). Patients were enrolled after comprehensive information checking that they (or their legal guardian) were not opposed to the study and the storage of their personal data. The electronic case report form has been the object of an approval of the national commission for Data Protection and Liberties (CNIL).

Aims and Endpoints

The primary objective of the study was to evaluate the consistence of dosing of IL1inhibitors in HRFs based on European Medicines Agency labeled recommendations.

The secondary aims were 1) to analyze the reasons for discrepancies with the product recommendations and 2) to assess the overall safety profile of IL-1 inhibitors in HRFs.

TABLE 1 | Patients characteristics and received IL1inhibitor.

Image: sector of the sector	Disease/Patient N°	Mutation (HGVS name)		Firs	st line IL1 inhibitor		Second line IL1 inhibitor		Third line IL1 inhibitor	
CARPS 1 TSMM by Tri-ASMAH CAN Sd Y Pattert's choice CARPS 2 DSDM by LawSSMPPI CAN Sd Y Advance event (metabolic disorder) CAN N CARPS 4 PSSDM (p.4.29507b) CAN N N Y Advance event (metabolic disorder) CAN N CARPS 4 PSSDM (p.4.29507b) CAN Sd Y Advance event (metabolic disorder) CAN N CARPS 5 PSSDM (p.4.29507b) CAN Sd N N N CARPS 6 PSSDM (p.4.29507b) CAN Sd N N N CARPS 6 PSSDM (p.4.29507b) CAN Sd N N N N CARPS 10 PSSDM (p.4.29507b) CAN Sd N N N N N CARPS 10 PSSDM (p.4.29507b) CAN Nd N N N N N CARPS 10 PSSDM (p.4.29507b) CAN Nd N N N N N C			Drug	Dosing group	Medication stopped? Y/N Reason	Drug	Dosing group	Medication stopped? Y/N Reason	Drug	Dosing group
CAPS 2D300 (p.4.gb303/er)ANBitY Scheduke with fine AN la to ANANInt.NCAPS 4P3000 (p.4.gb307)CANStdY Advense werk (intection)CANStdNCAPS 6P2000 (p.4.gb307)CANStdY Advense werk (intection)CANStdY Advense werk (intection)CANStdY Advense werk (intection)CANStdNCAPS 7TS4M (p. <i>TrisdAMM</i>)ANStdNNStdNNNCAPS 8P2000 (p.4.gb307)CANStdNNNNNNNCAPS 9R2000 (p.4.gb307)CANStdNNN <td< td=""><td>CAPS 1</td><td>T348M (p. Thr348Met)</td><td>CAN</td><td>Std</td><td>Y Patient's choice</td><td></td><td></td><td></td><td></td><td></td></td<>	CAPS 1	T348M (p. Thr348Met)	CAN	Std	Y Patient's choice					
CAPS 1 CAPS 2 CAPS 4 CAPS 4 CAPS 4 CAPS 4 CAPS 4 	CAPS 2	D303N (p.Asp303Asn)	ANA	Std	Y Scheduled switch from ANA to CAN	CAN	Int	Ν		
CAPS 1REDW (a/sg207/rs)CANSideY Advarse event (intection)CANSideNCAPS 5REDW (a/sg207/rs)CANSideNN<	CAPS 3	Y859C (p.Tyr859Cys)	CAN	Int	Ν					
CAPS 5PROW (p.Arg.2607m)CANIntY Adverse event (metabolic disorder)CANIntY Adverse event (metabolic disorder)CANIntCANCANCANMCAPS 6PECOW (p.Arg.2607m)CANSidNNN </td <td>CAPS 4</td> <td>R260W (p.Arg260Trp)</td> <td>CAN</td> <td>Std</td> <td>Y Adverse event (infection)</td> <td>CAN</td> <td>Std</td> <td>Ν</td> <td></td> <td></td>	CAPS 4	R260W (p.Arg260Trp)	CAN	Std	Y Adverse event (infection)	CAN	Std	Ν		
CAP8 6 P200W (p.Arg260Trp) CAN Std N CAP8 7 T384M (p.Trs48Mefn) AN Std N N N CAP8 8 P30W (p.Arg260Trp) CAN Std N N N N CAP8 91 ASSC (p.Arg260Trp) CAN Std N N N N CAP8 11 R200W (p.Arg260Trp) CAN N N N N N N CAP8 11 R200W (p.Arg260Trp) CAN N </td <td>CAPS 5</td> <td>R260W (p.Arg260Trp)</td> <td>CAN</td> <td>Int</td> <td>Y Adverse event (metabolic disorder)</td> <td>CAN</td> <td>Int</td> <td>Y Adverse event (nervous system disorder)</td> <td>CAN</td> <td>Int</td>	CAPS 5	R260W (p.Arg260Trp)	CAN	Int	Y Adverse event (metabolic disorder)	CAN	Int	Y Adverse event (nervous system disorder)	CAN	Int
CAPS 7TigAleNip Tri-deNingANA ANA StdStdY Scheduled switch from ANA to CAN NCAN 	CAPS 6	R260W (p.Arg260Trp)	CAN	Std	Ν					
CAPS 8RebWi (p.ArgeBCtrip)CANStidNCAPS 9ASSE (p.ArgeBCtrip)CANNNNCAPS 10P380W (p.ArgeBCtrip)CANNNNCAPS 11P380W (p.ArgeBCtrip)CANNNNCAPS 11P380W (p.ArgeBCtrip)CANNNNCAPS 12T384M (p.Thr283Med)CANNNNCAPS 13P380W (p.ArgeBCtrip)CANNNNCAPS 14P380W (p.ArgeBCtrip)CANNNNCAPS 15B280W (p.ArgeBCtrip)CANNNNCAPS 16P280W (p.ArgeBCtrip)CANSidNNCAPS 16B280W (p.ArgeBCtrip)CANSidNNCAPS 16B280W (p.ArgeBCtrip)CANSidNNCAPS 16B280W (p.ArgeBCtrip)CANSidNNCAPS 16B280W (p.ArgeBCtrip)CANSidNNTRAPS 1C709 (p.O;897/y)ANALowNNNTRAPS 1D28 (p.O;2587/n)ANALowNNNNTRAPS 2D28 (p.O;2587/n)ANALowNNNNTRAPS 2D28 (p.O;2587/n)ANALowNNNNTRAPS 3T500 (p.O;2587/n)ANALowNNNNTRAPS 3D28 (p.O;257/n)ANALowNNNNTRAPS 4<	CAPS 7	T348M (p.Thr348Met)	ANA	Std	Y Scheduled switch from ANA to CAN	CAN	Std	Ν		
CAPS 10CAPS 100CANStdNCAPS 10R5800 (p.Aq2807rp)CANIntNCAPS 11R5800 (p.Aq2807rp)CANStdY Scheduled switch from ANA to CANCANIntNCAPS 12T38480 (p.TrivAsMed)CANStdNNNNCAPS 13R5800v (p.Aq2807rp)CANIntNNNCAPS 14T38490 (p.Aq2807rp)CANIntNNNCAPS 15R2600v (p.Aq2807rp)CANNNNNNCAPS 16R2600v (p.Aq2807rp)CANStdNNNNCAPS 17R2600v (p.Aq2807rp)CANStdNNNNCAPS 18R260v (p.Aq2807rp)CANStdNNNNCAPS 18R260v (p.Aq2807rp)CANStdNNNNNCAPS 18R260v (p.Aq2807rp)CANStdNNNNNTRAPS 2CT0Y (p.Cys85ry)ANLowYNNNNNTRAPS 3D42E (p.Ag9710k)ANLowNNNNNNNTRAPS 4Y202 (p.Triv4DVpS)ANLowNNNNNNNTRAPS 4D420 (p.Ag72601r)ANLowNNNNNNNNTRAPS 4Y202 (p.Triv4DVpS)ANLowNNN <td>CAPS 8</td> <td>R260W (p.Arg260Trp)</td> <td>CAN</td> <td>Std</td> <td>Ν</td> <td></td> <td></td> <td></td> <td></td> <td></td>	CAPS 8	R260W (p.Arg260Trp)	CAN	Std	Ν					
CAPS 10PCROW (p.Aq2607r) (p.Aq2607r)CANintNCAPS 11Re60W (p.Aq2607r) (p.Aq2607r)CANSidY Schulied switch from ANA to CANCANIntNCAPS 12Re60W (p.Aq2607r) (p.Aq2607r)CANIntNNNNCAPS 13Re60W (p.Aq2607r) (p.Aq2607r)CANIntNNNNCAPS 14RAGW (p.Aq2607r) (p.Aq2607r)CANNNNNNNCAPS 16Re60W (p.Aq2607r) (p.Aq2607r)CANSidNNNNNCAPS 17Re60W (p.Aq2607r) (p.Aq2607r)CANSidNNNNNNCAPS 17Re60W (p.Aq2607r)CANSidNNN <td>CAPS 9</td> <td>A352V (p.Ala352Val)</td> <td>CAN</td> <td>Std</td> <td>Ν</td> <td></td> <td></td> <td></td> <td></td> <td></td>	CAPS 9	A352V (p.Ala352Val)	CAN	Std	Ν					
CAPS 11CROW (p./q2607/p)ANA AVAStdY Scheduled switch from ANA to CAN ANA AVACANIntNCAPS 12T348M (p.Thr.438.Mef)CANIntNNN <td>CAPS 10</td> <td>R260W (p.Arg260Trp)</td> <td>CAN</td> <td>Int</td> <td>Ν</td> <td></td> <td></td> <td></td> <td></td> <td></td>	CAPS 10	R260W (p.Arg260Trp)	CAN	Int	Ν					
CAPS 12TABMA (a, Third-Aldwell)CANStillNCAPS 13R260W (a, Arg260Trp)CANIntNNCAPS 14TABMA (a, Third-Aldwell)CANIntNNCAPS 15R260W (a, Arg260Trp)CANNNNCAPS 16R260W (a, Arg260Trp)ANAStillY Burden of injectionsCANStillYCAPS 16R260W (a, Arg260Trp)CANStillNNNCAPS 17R260W (a, Arg260Trp)CANStillNNCAPS 18R260W (a, Arg260Trp)CANStillNNCAPS 17C29S (a, C)\$\$5558)ANAStillNLowNTRAPS 10C29S (a, C)\$\$5558)ANAStillNLowNTRAPS 31C29S (a, C)\$\$5558)ANALowNNNTRAPS 40C29S (a, C)\$\$70Hn)ANALowNNLowNTRAPS 40Y20C (a, Thir340Crp)ANALowNNNNTRAPS 40Y20C (a, C)\$72PhingANALowNLowNNTRAPS 50D42E (a, Asp42Ght)ANALowNLowNNNTRAPS 40B632 (a, Lip2 (a) M6492 M4492 M4694492 M46944	CAPS 11	R260W (p.Arg260Trp)	ANA	Std	Y Scheduled switch from ANA to CAN	CAN	Int	Ν		
CAPS 13PEROW (a.Arg.26077p)CANIntNCAPS 14T34BM (p.Arg.26077p)CANIntNCAPS 15PEROW (a.Arg.26077p)CANNNCAPS 16PEROW (a.Arg.26077p)CANStdYPatient's choiceCAPS 17PEROW (a.Arg.26077p)CANStdNCAPS 18PEROW (a.Arg.26077p)CANStdNCAPS 18PEROW (a.Arg.26077p)CANStdNTFAPS 1C2SS (a.Cys55Ser)ANAStdYTFAPS 2C707 (p.Cys977y)ANAStdYTFAPS 2C707 (p.Cys977y)ANALowNTFAPS 3D42E (a.Agp.71Gk)ANALowNTFAPS 4Y20C (a.Tr)r49C/s9ANALowNTFAPS 5T50M (a.Tr)r79Mef)ANALowNTFAPS 6C345 (a.Cys72Phe)ANALowNTFAPS 6C345 (a.Cys72Phe)ANALowNTFAPS 7D42E (a.Agp.71Gk)ANALowNTFAPS 8RS20 (a.Cys72Phe)ANALowNTFAPS 8RS20 (a.Cys72Phe)ANALowNTFAPS 9RS20 (a.Cys72Phe)ANALowNTFAPS 9RS20 (a.Cys72Phe)ANALowNTFAPS 9RS20 (a.Cys72Phe)ANALowNTFAPS 9RS20 (a.Cys72Phe)ANALowNTFAPS 9RS20 (a.Cys72Phe)ANALowNTFAPS 9RS20 (a.Cys72Ph	CAPS 12	T348M (p.Thr348Met)	CAN	Std	Ν					
CAPS 16TradeMing TradingerCANIntNCAPS 16P600W (p.Arg260Trp)ANAStdY Burden of injectionsCANStdYCANStdCAPS 17P600W (p.Arg260Trp)CANStdNStdYDetember 1CAPS 18P600W (p.Arg260Trp)CANStdNStdYStdYCAPS 17C208 (p.Arg260Trp)CANStdNStdNStdNTPAPS 10C208 (p.Arg260Trp)CANStdY Scheduled switch from ANA to CANCANNNNTPAPS 20C70Y (p.Cy659Sry1)ANALowY Scheduled switch from ANA to CANCANNNNNTPAPS 31C208 (p.Arg27TGk)ANALowY Scheduled switch from ANA to CANCANNNNNNTPAPS 40Y202 (p.Thy45Cy)ANALowY Scheduled switch from ANA to CANCANLowNNNNNTPAPS 51TS06 (p.Cy672Phe)ANALowNN <td>CAPS 13</td> <td>R260W (p.Arg260Trp)</td> <td>CAN</td> <td>Int</td> <td>Ν</td> <td></td> <td></td> <td></td> <td></td> <td></td>	CAPS 13	R260W (p.Arg260Trp)	CAN	Int	Ν					
CAPS 15R260W (p.Arg260Trp)CANIntNCAPS 16R260W (p.Arg260Trp)ANAStdY Burden of injectionsCANStdPatient's choiceCAPS 17R260W (p.Arg260Trp)CANStdN </td <td>CAPS 14</td> <td>T348M (p.Thr348Met)</td> <td>CAN</td> <td>Int</td> <td>Ν</td> <td></td> <td></td> <td></td> <td></td> <td></td>	CAPS 14	T348M (p.Thr348Met)	CAN	Int	Ν					
CAPS 16P260W (p./rg/2807/p)ANAStdY Burden of injectionsCANStdYCANStdPatient's choiceCAPS 17R260W (p./rg/2807/p)CANStdNNN <td< td=""><td>CAPS 15</td><td>R260W (p.Arg260Trp)</td><td>CAN</td><td>Int</td><td>Ν</td><td></td><td></td><td></td><td></td><td></td></td<>	CAPS 15	R260W (p.Arg260Trp)	CAN	Int	Ν					
Patient's choice CAPS 17 R260W (b.Arg260Tp) CAN Std N CAPS 18 R260W (b.Arg260Tp) CAN Std N TRAPS 1 C29S (b.C)55558) ANA Std Y Scheduled switch from ANA to CAN CAN Low N TRAPS 2 C70Y (b.C)59597y1 ANA Low Y CAN Low N TRAPS 3 D42E (b.Asp71Ghl) ANA Low N N N N TRAPS 4 Y20C (b.Thy49Cys) ANA Low N	CAPS 16	R260W (p.Arg260Trp)	ANA	Std	Y Burden of injections	CAN	Std	Y	CAN	Std
CAPS 17R280W (p.Arg2807/p)CANStdNCAPS 18R260W (p.Arg2807/p)CANStdNTRAPS 1C29S (p.Cys858)ANAStdY Scheduled switch from ANA to CANCANLowNTRAPS 2C70Y (p.Cys997/n)ANALowY Scheduled switch from ANA to CANCANLowNTRAPS 3D42E (p.Asp71Glu)ANALowNNot effective (on demand)NNTRAPS 4Y20C (p.Try490/ps)ANALowNNNTRAPS 5T50M (p.Arg280/r)ANALowNNNTRAPS 6C49F (p.Cys727/r)ANALowNNNTRAPS 7D42E (p.Asp4261u)ANALowNNNTRAPS 7D42E (p.Asp4261u)ANAStdY Not effective (on demand)CANStdY not effectivePMF 11692*/7728A (p.Me694/alp/Mef694/alpANAStdY Not effective (on demand)CANLowNPMF 2M694/M694V (p.Mef694/alp/Mef694/alpANAStdY Adverse event (kin disorder)CANLowNPMF 2M694/M694V (p.Mef694/alp/Mef694/alpANAStdY Adverse event (kin disorder)CANLowNPMF 3M694/M694V (p.Mef694/alp/Mef694/alpANAStdY Adverse event (kin disorder)CANLowNPMF 4M694/M694V (p.Mef694/alp/Mef694/alpANALowNNNNPMF 5M694/M694V (p.Mef694/alp/Mef694/alp </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Patient's choice</td> <td></td> <td></td>								Patient's choice		
CAPS 18R260W (p.Arg/260Tm)CANStdNTRAPS 1C29S (p.C);cSSSer)ANAStdY Scheduled switch from ANA to CANCANLowNTRAPS 2C70Y (p.C);S9Tm/ANALowYChanLowNTRAPS 3D42E (p.Asp.716/h)ANALowNConNNTRAPS 4Y20C (p.Thy49Cys)ANALowNNNNTRAPS 5T50M (p.Thr/37Met)ANALowNNNNTRAPS 6C45 (p.C);s72Ph)ANALowNNNNTRAPS 7D42E (p.Asp.21Gin)ANAStdY Not effective (on demand)CANLowNNTRAPS 8R320 (p.Arg)12Gin)ANAStdY Not effective (on demand)CANLowNNFMF 1I692*V726A (p.M692Del/p.Va1726A(a)ANAStdY Not effective (on demand)CANLowNNFMF 3M694V/ME94V (p.Met694Val/p.Met694ValANAStdY Not effective (on demand)CANLowNNFMF 4M694V/ME94V (p.Met694Val/p.Met694ValANALowY Not effectiveCANLowNNFMF 3M694V/ME94V (p.Met694Val/p.Met694ValANALowNNNNNNFMF 4M694V/ME94V (p.Met694Val/p.Met694ValANALowNNNNNNFMF 5M694V/ME94V (p.Met694Val/p.Met694ValANALowN<	CAPS 17	R260W (p.Arg260Trp)	CAN	Std	Ν					
TRAPS 1C28S (p.C)sSS8r)ANAStdY Checkled switch from ANA to CANCANLowNTRAPS 2C70Y (p.C)s97/nANALowNCANLowNTRAPS 3D42E (p.Asp71Gk/)ANALowNNTRAPS 4Y2C0 (p.Thy49Cyrs)ANALowNNTRAPS 5TSGM (p.Thr/Sthef)ANALowNNTRAPS 6C43F (p.C)s72Phe)ANALowNNTRAPS 7D42E (p.Asp72Gk/)ANALowNNTRAPS 6C43F (p.C)s72Phe)ANALowNNTRAPS 7D42E (p.Asp72Gk/)ANAStdY Not effective (on demand)CANStdY not effectiveTRAPS 7D42E (p.Asp72Gk/)ANAStdY Not effective (on demand)CANLowNFMF 11992'/YT28A (p.Me694/a/)/MAR44/ANAStdY Not effective (on demand)CANLowNFMF 2M694/VM694 V(p.Mef694/a/)/MAR44/ANALowNLowNNFMF 2M694/VM694 V(p.Mef694/a/)/MAR64/AANALowNLowNFMF 3M694/VM694 V(p.Mef694/a/)/MAR64/AANALowNLowNFMF 6M694/VMT (p.Mef694/a/)/MAR64/AANALowNNFMF 6M694/VME94 V(p.Mef694/a/)/MAR64/A/ANALowNNFMF 7M694/VM694 V(p.Mef694/a/)/MAR64/A/ANALowNNFMF 6M694/VME94 V(p.Mef	CAPS 18	R260W (p.Arg260Trp)	CAN	Std	Ν					
TRAPS 2C70Y (p.C)9997r/nANALowYCANLowNTRAPS 342E (p.Asp.71Glv)ANALowNTRAPS 4Y20C (p.Thy49Cys)ANALowY Scheduled switch from ANA to CANCANLowNTRAPS 5T50M (p.Thr79Meft)ANALowNLowNLowNTRAPS 6C4S (p.C)sr2Pre)ANALowNLowNLowNTRAPS 7D42E (p.Asp.42Glv)ANALowNLowNLowNTRAPS 8R920 (p.Arg121Gin)ANAStdY Adverse event (kin disorder)CANLowNLowNFMF 11692/Y726A (p.Ide692De/p.Val726Ak)ANALowY Adverse event (kin disorder)CANLowNLowNFMF 4M694/WM694 (p.Met694Val/p.Met694ValANALowY Adverse event (kin disorder)CANLowNLowNFMF 5M694/W694 (p.Met694Val/p.Met694ValANALowY Adverse event (kin disorder)CANLowNLowNFMF 6M694/WM7 (p.Met694Val/p.Met694ValANALowY Not effectiveCANLowNLowNFMF 7M694/WM694 (p.Met694Val/p.Met694ValANALowNNLowNLowNFMF 7M694/WM694 (p.Met694Val/p.Met694ValANALowNLowNLowNLowNFMF 7M694/WM694 (p.Met694Val/p.Met694ValANA <t< td=""><td>TRAPS 1</td><td>C29S (p.Cys58Ser)</td><td>ANA</td><td>Std</td><td>Y Scheduled switch from ANA to CAN</td><td>CAN</td><td>Low</td><td>Ν</td><td></td><td></td></t<>	TRAPS 1	C29S (p.Cys58Ser)	ANA	Std	Y Scheduled switch from ANA to CAN	CAN	Low	Ν		
TRAPS 3Date (p.Asp/T)G(u)ANALowNTRAPS 4Y20C (p.Th/49C)s)ANALowNTRAPS 5TSG/(p.C)s72/Phe)ANALowNTRAPS 6C43F (p.C)s72/Phe)ANALowNTRAPS 7C42E (p.Asp/22Gi/)ANALowNTRAPS 7C42E (p.Asp/22Gi/)ANALowNTRAPS 7C42E (p.Asp/22Gi/)ANALowNTRAPS 7Dig/(p.Asp/22Gi/)ANALowNTRAPS 7Dig/(p.Asp/22Gi/)ANALowNTRAPS 7Dig/(p.Asp/22Gi/)ANALowNTRAPS 7Dig/(p.Asp/22Gi/)ANALowNTRAPS 7Dig/(p.Asp/22Gi/)ANALowNTRAPS 7Dig/(p.Asp/22Gi/)ANALowNTRAPS 7Dig/(p.Asp/12Gi/Ash/2As/Asi/Asi/Asi/Asi/Asi/Asi/Asi/Asi/Asi/A	TRAPS 2	C70Y (p.Cys99Tyr)	ANA	Low	Y	CAN	Low	Ν		
TRAPS 3 D42E (p.Asp71Glu) ANA Low N TRAPS 4 Y2OC (p.Th/940/S)S ANA Low N Low N TRAPS 5 TS0M (p.Th/79Met) ANA Low N Low N TRAPS 5 TS0M (p.Th/79Met) ANA Low N Low N TRAPS 7 D42E (p.Asp72Glu) ANA Low N Low Vant effective (on demand) CAN Std Y not effective Other Low N TRAPS 8 R920 (p.Arg12Glu) ANA Std Y Adverse event (skin disorder) CAN Low N Low					Not effective (on demand)					
TRAPS 4Y20C (p. Thy 49C ys)ANALowY Scheduled switch from ANA to CANCANLowNTRAPS 5T50M (p. Thr 79Met)ANALowN<	TRAPS 3	D42E (p.Asp71Glu)	ANA	Low	N					
TRAPS 5TSOM (p. 7hr/9Met)ANALowNTRAPS 6C43F (p. Ops72Phe)ANALowNTRAPS 7D42E (p. Aps42diu)ANALowNTRAPS 8R920 (p. Arg121Gin)ANAStdY Not effective (on demand)CANStdY not effectiveTFM 1I692'/V726A (p. Ide692/bal/) Xi1726A(a)ANAStdY Adverse event (skin disorder)CANLowNFMF 1I692'/V726A (p. Ide692/bal/) Xi1726A(a)ANAStdY Adverse event (skin disorder)CANLowNFMF 2M694V/Met694/al/) Met694/al/) Met694/al/) Met694/al/) Met694/al/) Met694/al/) Met694/al/) Met694/al/) Met694/al/) Met694/al/ANALowY RemissionFMF 4M694V/Mf0.Met694/al/MMTANALowNYFMF 7M694V/M694V (p. Met694/al/) Met694/al/)ANALowNFMF 7M694V/Mf0.Met694/al/) Met694/al/ANALowNFMF 8M694V/Mf0.Met694/al/, Met694/al/ANALowNFMF 9M694V/Mf0.Met694/al/, Met694/al/ANALowNFMF 10M694V/Mf0.Met694/al/, Met694/al/ANALowNFMF 11M694V/Mf0.Met694/al/, Met694/al/ANALowNFMF 12M694V/M694V (p. Met694/al/) Met694/al/ANAStdY Burden of injectionsCANLowFMF 11M694V/M694V (p. Met694/al/) Met694/al/ANALowY Burden of injectionsCANLowLowFMF 12M694V/M694V (p. Met694/al/) Met694/al/ANA	TRAPS 4	Y20C (p.Thy49Cys)	ANA	Low	Y Scheduled switch from ANA to CAN	CAN	Low	Ν		
TRAPS 6 C43F (p. Cys72Phe) ANA Low N TRAPS 7 D42E (p. Asp42Glu) ANA Low N TRAPS 8 R920 (p. Arg121Gln) ANA Std Y Not effective (on demand) CAN Std Y not effective Other FMF 1 (692'/T26A (p. /le692Del/p. Val726Al) ANA Std Y Adverse event (skin disorder) CAN Low N FMF 2 M694/VM694V (p. Met694Val/p. Met694Val) ANA Low Y Adverse event (hepatitis) CAN Low N FMF 3 M694/VM694V (p. Met694Val/p. Met	TRAPS 5	T50M (p.Thr79Met)	ANA	Low	Ν					
TRAPS 7 D42E (p.Asp42Glu) ANA Low N TRAPS 8 R920 (p.Arg121Gln) ANA Std Y Not effective (on demand) CAN Std Y not effective Other FMF 1 16921/V726A (p.16692Del/p.Va1726A) ANA Std Y Adverse event (sin disorder) CAN Low N FMF 2 M694V/M694V (p.Met694Val/p.Met694Val ANA Low Y Adverse event (spatitis) CAN Low N FMF 3 M694V/M694V (p.Met694Val/p.Met694	TRAPS 6	C43F (p.Cys72Phe)	ANA	Low	Ν					
TRAPS 8R92Q (p.Arg121Gin)ANAStdY Not effective (on demand)CANStdY not effectiveOtherFMF 11692'/V726A (p./le692De/p.Val726A)ANAStdY Adverse event (skin disorder)CANLowNFMF 2M694V/M694V (p.Met694Va/p.Met694Va)ANALowY Adverse event (skin disorder)CANLowNFMF 3M694V/M694V (p.Met694Va/p.Met694Va)ANALowNLowNLowNFMF 4M694V/ME694Va/p.Met694Va/p.Met694Va)ANALowY Not effectiveCANStdNNFMF 5M694V/M694V (p.Met694Va/p.Met694Va)ANAStdY RemissionFMF 6M694V/M694V (p.Met694Va/p.Met694Va)ANAStdY RemissionFMF 7M694V/M694V (p.Met694Va/p.Met694Va)ANALowN <t< td=""><td>TRAPS 7</td><td>D42E (p.Asp42Glu)</td><td>ANA</td><td>Low</td><td>Ν</td><td></td><td></td><td></td><td></td><td></td></t<>	TRAPS 7	D42E (p.Asp42Glu)	ANA	Low	Ν					
FMF 1I692*/V726A (p.lle692Del/p.Val726A(a)ANAStdY Adverse event (skin disorder)CANLowNFMF 2M694V/M694V (p.Met694Val/p.Met694Va)ANALowY Adverse event (hepatitis)CANLowNFMF 3M694V/M694V (p.Met694Val/p.Met694Va)CANLowNFMF 4M694V/MC (p.Met694Val/p.Met694Val)ANALowNFMF 5M694V/MC (p.Met694Val/p.Met694Val)ANAStdY RemissionFMF 6M694V/M694V (p.Met694Val/p.Met694Val)ANALowN <td>TRAPS 8</td> <td>R92Q (p.Arg121Gln)</td> <td>ANA</td> <td>Std</td> <td>Y Not effective (on demand)</td> <td>CAN</td> <td>Std</td> <td>Y not effective</td> <td>Other</td> <td></td>	TRAPS 8	R92Q (p.Arg121Gln)	ANA	Std	Y Not effective (on demand)	CAN	Std	Y not effective	Other	
FMF 2M694V/M694V (p.Met694Val/p.Met694Val	FMF 1	1692*/V726A (p.1/e692Del/p.Val726Ala)	ANA	Std	Y Adverse event (skin disorder)	CAN	Low	Ν		
FMF 3M694V/M694V (p.Met694Val/p.Met694Val)CANLowNFMF 4M694V/WT (p.Met694Val/WT)ANALowY Not effectiveCANStdNFMF 5M694V/M694V (p.Met694Val/p.Met694Val)ANAStdY RemissionFMF 6M694V/WT (p.Met694Val/p.Met694Val)ANALowNFMF 7M694V/M694V (p.Met694Val/p.Met694Val)CANLowNFMF 8M694V/WT (p.Met694Val/p.Met694Val)CANLowN	FMF 2	M694V/M694V (p.Met694Val/p.Met694Val)	ANA	Low	Y Adverse event (hepatitis)	CAN	Low	Ν		
FMF 4M694V/MT (p.Met694Val/WT)ANALowY Not effectiveCANStdNFMF 5M694V/M694V (p.Met694Val/p.Met694Val)ANAStdY Remission<	FMF 3	M694V/M694V (p.Met694Val/p.Met694Val)	CAN	Low	Ν					
FMF 5M694V/M694V (p.Met694Val/p.Met694Val)ANAStdY RemissionFMF 6M694V/WT (p.Met694Val/WT)ANALowNFMF 7M694V/M694V (p.Met694Val/p.Met694Val)CANLowNFMF 8M694V/M594V (p.Met694Val/p.Met694Val)ANALowNFMF 9M694V/WT (p.Met694Val/WT)CANLowNFMF 10M694V/M694V (p.Met694Val/WT)ANALowNFMF 11M694V/M694V (p.Met694Val/WT)ANALowNFMF 12M694V/M694V (p.Met694Val/P.Met694Val)ANAStdY Burden of injectionsCANLowCANFMF 13M694I/M694V (p.Met694Val/P.Met694Val)ANAStdY Not effectiveOtherFMF 14M694V/M694V (p.Met694Val/P.Met694Val)ANAStdY Not effectiveOtherFMF 13M694I/M694V (p.Met694Val/P.Met694Val)ANAStdY RemissionCANLowMKD 1K130/N205D (p.Lys 13Gin/p.Asn205Asp)ANAStdY Scheduled switch from ANA to CANCANLowNMKD 3I268T/v3771 (p.Ile268Thr/p.Val377lle)CANLowNNLowN	FMF 4	M694V/WT (p.Met694Val/WT)	ANA	Low	Y Not effective	CAN	Std	Ν		
FMF 6M694V/WT (p.Met694Val/VT)ANALowNFMF 7M694V/M694V (p.Met694Val/p.Met694Val)CANLowNFMF 8M694V/M694V (p.Met694Val/p.Met694Vla)ANALowNFMF 9M694V/WT (p.Met694Val/VT)CANLowNFMF 10M694V/M504Val/VAI/D.Met694Val/VT)ANALowNFMF 11M694V/M504Val/VAI/D.Met694Val/VAI/DANAStdY Burden of injectionsCANLowY RemissionFMF 12M694V/M694V (p.Met694Val/p.Met694Val)ANAStdY Burden of injectionsCANLowCANLowFMF 13M694I/M694V (p.Met694Val/p.Met694Vla)ANAStdY Not effectiveOtherFMF 14K13Q/N205D (p.Lys13Gin/p.Asr205Asp)ANAStdY RemissionCANLowNFMF 13M694I/M694I (p.Met694Ile/p.Met694Ile)ANAStdY RemissionCANLowN <td>FMF 5</td> <td>M694V/M694V (p.Met694Val/p.Met694Val)</td> <td>ANA</td> <td>Std</td> <td>Y Remission</td> <td></td> <td></td> <td></td> <td></td> <td></td>	FMF 5	M694V/M694V (p.Met694Val/p.Met694Val)	ANA	Std	Y Remission					
FMF 7M694V/M694V (p.Met694Val/p.Met694Val/p.Met694Val/p.Met694Val/p.Met694Val/p.Met694Val/p.Met694Val/p.Met694Val/pCANLowNFMF 8M694V/MF (p.Met694Val/WT)CANLowNFMF 9M694V/WT (p.Met694Val/WT)CANLowNFMF 10M694V/MF (p.Met694Val/WT)ANALowNFMF 11M694V/M694V (p.Met694Val/p.Me	FMF 6	M694V/WT (p.Met694Val/WT)	ANA	Low	Ν					
FMF 8M694V/M694V (p.Met694IIe/p. Met694IIe/p. Met694IIe/p. Met694IIe/p. Met694IIe/p. Met694IIe/p. Met694Va//VT)ANALowNFMF 10M694V/WT (p.Met694Va//WT)ANALowNFMF 11M694V/M694V (p.Met694Va//p.Met694Va)ANAStdY Burden of injectionsCANLowY RemissionCANLowFMF 12M694V/M694V (p.Met694Val/p.Met694Va)ANAStdY Burden of injectionsCANLowY RemissionCANLowFMF 13M694I/M694I (p.Met694Val/p.Met694IIe/p. Met694IIe/p. M	FMF 7	M694V/M694V (p.Met694Val/p.Met694Val)	CAN	Low	Ν					
FMF 9M694V/WT (p.Met694Val/WT)CANLowNFMF 10M694V/WT (p.Met694Val/WT)ANALowNFMF 11M694V/M694V (p.Met694Val/p.Met694Val)ANAStdY Burden of injectionsCANLowY RemissionCANLowFMF 12M694V/M694V (p.Met694Val/p.Met694Val)CANLowY Adverse event (infection)YYYYYYFMF 13M694I/M694I (p.Met694Ile/p.Met694Ile)ANAStdY Not effectiveOtherYYYYYYMKD 1K13Q/N205D (p.Lys13Gln/p.Asn205Asp)ANAStdY RemissionCANLowNYY	FMF 8	M694V/M694V (p.Met694lle/p. Met694lle)	ANA	Low	Ν					
FMF 10M694V/WT (p./Met694Val/WT)ANALowNFMF 11M694V/M694V (p./Met694Val/p./Met694Va	FMF 9	M694V/WT (p.Met694Val/WT)	CAN	Low	Ν					
FMF 11M694V/M694V (p.Met694Val/p.Met694Va	FMF 10	M694V/WT (p.Met694Val/WT)	ANA	Low	Ν					
FMF 12M694V/M694V (p.Met694Val/p.Met694Va	FMF 11	M694V/M694V (p.Met694Val/p.Met694Val)	ANA	Std	Y Burden of injections	CAN	Low	Y Remission	CAN	Low
FMF 13M694I/M694I (p.Met694Ile/p.Met694Il	FMF 12	M694V/M694V (p.Met694Val/p.Met694Val)	CAN	Low	Y Adverse event (infection)					
MKD 1K13Q/N205D (p.Lys13Gln/p.Asn205Asp)ANAStdY RemissionCANLowNMKD 2D204E/V377I (p.Asp204Glu/p.Val377Ile)ANAStdY Scheduled switch from ANA to CANCANLowNMKD 31268T/V377I (p.lle268Thr/p.Val377Ile)CANLowNNStdN	FMF 13	M694I/M694I (p.Met694IIe/p.Met694IIe)	ANA	Std	Y Not effective	Other				
MKD 2 D204E/V377I (p.Asp204Glu/p.Val377Ile) ANA Std Y Scheduled switch from ANA to CAN CAN Low N MKD 3 1268T/V377I (p.Ile268Thr/p.Val377Ile) CAN Low N	MKD 1	K13Q/N205D (p.Lys13Gln/p.Asn205Asp)	ANA	Std	Y Remission	CAN	Low	Ν		
MKD 3 1268T/V3771 (p.1le268Thr/p.Val3771le) CAN Low N	MKD 2	D204E/V377I (p.Asp204Glu/p.Val377lle)	ANA	Std	Y Scheduled switch from ANA to CAN	CAN	Low	Ν		
	MKD 3	1268T/V377I (p.lle268Thr/p.Val377lle)	CAN	Low	Ν					

(Continued on following page)

Disease/Patient N°	Mutation (HGVS name)		Firs	t line IL1 inhibitor		Second line	IL1 inhibitor	Third	ine IL.
		Drug	Dosing group	Medication stopped? Y/N Reason	Drug	Dosing group	Medication stopped? Y/N Reason	Drug	Dos
MKD 4	G309S/R388X (p.Gl/309Ser/p.Arg388*)	CAN	Low	z					
MKD 5	G311R/V3771 (p.Gly311Arg/p.Val377lle)	ANA	Std	Y Scheduled switch from ANA to CAN	CAN	Std	Z		
MKD 6	L51F/WT (p.Leu51Phe/WT)	CAN	Int	Z					
Low = group 1: patient Std = group 2: patient r	receiving lower than recommended dosage. eceiving standard dosage.								
Int = group 3: patient re ANA = anakinra. CAN =	ceiving an intensified dosage of IL-1 inhibitor. canakinumab.								
The treatment group of	the patients (low, standard or intensified) was d	defined on	the dosage received	d at the last visit (or at the last visit before di	iscontinua	tion of the studied II	1 inhibitor).		

Assessment of the Accordance of the Received Dosage of Medication with the Recommended Dosing Regimen

All the patients who received at least one IL1 inhibitor for colchicine resistant FMF, MKD, TRAPS and CAPS were assessed. Starting and ending date of the IL-1 inhibition were notified so that total exposure time for each IL-1 inhibitor, expressed in patient-years, could be calculated.

To study the different dosage regimens, we considered the dosage of IL-1 inhibitor received at the last visit (or at the last visit before discontinuation of the studied IL-1 inhibitor). Patients were classified into three groups: group 1/lower than recommended dosage, group 2/standard dosage and group 3/ intensified dosage. For anakinra, standard dose was defined as 100 mg/day (among adults) or 2 (±0.5) mg/kg/day (among children) (European Medicines Agency, 2018a). For canakinumab the standard dose depended on the indication: for CAPS-patients the standard dose was defined as 150 mg (or 2 (± 0.5) mg/kg) every 8 weeks, whereas the standard dose for crFMF, MKD and TRAPS patient was the dose recommended by the European Medicines Agency: 150 mg (or $2 (\pm 0.5)$ mg/kg) every 4 weeks (European Medicines Agency, 2018b). Patients treated with lower or less frequent injections were considered as receiving lower than recommended doses, whereas those receiving higher dosages or more frequent injections were considered as receiving intensified dosages of canakinumab.

Analysis of the Reasons for Discrepancies with the **Product Recommendations**

To analyze the reasons for accordance or discrepancies of the different dosage regimens with the product recommendations, a descriptive analysis of the treatment modalities of the patients treated with IL-1 inhibitors was performed.

Assessment of the Overall Safety Profile of IL-1 Inhibitors

Frequency and description of adverse events were retrieved according to the medDRA terminology. For each adverse event, investigators had to indicate the intensity among "no effect", "mild", "moderate", "severe" and "very severe," the seriousness with the necessity of an hospitalization or not, the relationship between the medication and the event among "not related," "not likely," "possible," "probable," and "definitely" and the consequence on the administration of the treatment among "no action," "drug interrupted," "drug discontinued," "dose reduced". Adverse events were expressed both as absolute number of events during the whole follow-up and as number of events/100 patients/year.

RESULTS

Forty-five French patients who received at least once an IL-1 inhibitor, either anakinra or canakinumab or both, were identified in the JIR cohort and included for analysis. Table 1 summarizes patient's characteristics with their treatments. Anakinra was the most given treatment (25/45 - 56%),

ng group inhibitor



especially in FMF (9/13 – 69%) and TRAPS (8/8 – 100%) patients. The total treatment exposure to anakinra and canakinumab represented 54 and 202.9 patient-years respectively.

Figure 1 summarizes the actual doses received at the last visit (or at the last visit before discontinuation of the studied IL-1 inhibitor) according to the different diseases. Group 1 (lower dosage than in product recommendations) constituted 43% of the patients, regardless the type of IL-1 inhibitor. This was especially true for FMF, TRAPS and MKD patients on canakinumab with 100%, 75%, and 66% of patients respectively who received less than standard dose (i.e. 150 mg or 2 mg/kg every 4 weeks). Group 2 (standard dose) concerned 42% of the patients; whereas an intensified dose of IL-1 inhibitors (group 3) was given to 15% of the patients: 44% of CAPS patients and 17% of MKD patients received in our cohort higher doses than the recommended standard dose whereas neither FMF nor TRAPS patients required the intensified maintenance dose (i.e. 300 mg or 4 mg/kg every 4 weeks).

The lower dosages in our cohort than the ones recommended in the summary of product characteristics (SPC) were explained by different treatment regimens:

• Fifty percent of the patients (i.e 2 FMF and 3 TRAPS patients) treated with anakinra who received less than the recommended dose were treated with an on-demand regimen (anakinra administration only during flares), the other half received either a maintenance treatment by injections every other day instead of daily injections, or lower daily doses.

• Administration modalities for canakinumab also varied: One CAPS and one FMF patient received an "ondemand" regimen, i.e., an injection of canakinumab only if clinical and biological symptoms appeared. The other lower dose regimens involved patients with the new indication of canakinumab (i.e., FMF, TRAPS and MKD): they received less frequent injections than those stipulated in the SCP, varying from an injection every 10 weeks to every 6 weeks.

Concerning reported adverse eventsoccuring while on IL1 inhibitors (**Table 2**), 6 led to a therapeutic discontinuation, whereas 40 other adverse events possibly, probably or certainly related to IL1 inhibition were reported. The global incidence of adverse events with IL1 inhibition was 17.1 per 100 patient/years. No significant difference in the incidence of adverse events was found between anakinra or canakinumab therapy (p = 0.55). No link could be established between the frequency of adverse events and the dosage of IL1 inhibitor received. Especially of the nine patients with a side effect considered as serious or very serious by the investigator, three received an intensified dosage regimen. No life-threatening adverse events were retrieved in our study.

The global drug retention rate was higher for canakinumab than anakinra (**Figure 2**): 33 out of 36 patients (92%) that ever received canakinumab continued the treatment at the end of the study period, whereas this was only the case for 7 out of 25 (29%) of anakinra treated patients (p < 0.0001).

TABLE 2 | Reported side effects with IL1 inhibitors during the study period.

	Anakinra (24 patients 54 pts/year)	Canakinumab (36 patients/202,9 pts/year)
Infections/infestations	7	26
Hepatobiliary disorders	1	1
Metabolism and/or nutrition disorders	0	1
Nervous system disorders	0	3
Skin and/or subcutaneous tissue disorders	3	1
Surgical and/or medical procedures	0	2
Vascular disorders	0	1
Total	11	35



DISCUSSION

This study assessed the dosing regimen of IL-1 inhibitors in patients with a monogenic auto-inflammatory disease. During the study period, in France licensed use of IL-1 inhibitors was possible only in CAPS patients. Nevertheless the French healthcare organization enables physicians belonging to secondary or tertiary care centers for rare diseases to prescribe off labeled drugs and our study focused on these patients.

Almost half of the patients received lower dosages of IL-1 inhibitors than the recommended standard dose. These lower dosage regimens concerned 60% of the patients with the more recent licensed indications of IL1-inhibitors: crFMF, TRAPS and MKD (De Benedetti et al., 2018; European Medicines Agency, 2018b). Especially, canakinumab injections rate was far lower and varied greatly from one patient to another with injections ranging from every 6 to every 10 weeks. This was probably due to the fact that patients received doses based upon the licensed use of canakinumab (ie CAPS, in whom the standard dose is lower than in the other recurrent autoinflammatory fever syndromes). Indeed the publication of the phase 3 Canakinumab Pivotal Umbrella Study in Three Hereditary Periodic Fevers (CLUSTER) study (De Benedetti et al., 2018), defining the standard dose of 150 mg (or 2 mg/kg) every 4 weeks, occurred after the end of our study. Nevertheless it is a striking finding that in a real-life setting, lower doses than the anticipated standard dose seem sufficient to control the disease. Moreover it seems to show that the need for IL1 inhibitors is not uniform: while 100% of patients with crFMF responded to low doses of interleukin 1 inhibition, patients with MKD required overall higher doses, with a need of intensified doses observed only in this group. TRAPS patients seem to display an intermediate profile of interleukin 1 thresholds, with more various needs of the level of IL-1 inhibition to control the disease. Thus results show that the optimal dosage for properly treating any of these diseases is not yet fully defined.

The other main reason for lower dosages was an on-demand treatment strategy in FMF and TRAPS patients. An on-demand

strategy was previously described only in 3 studies with anakinra (Bodar et al., 2011; Grimwood et al., 2015; Babaoglu et al., 2019). In a real life setting, this strategy seems to be a realistic treatment option for selected patients (equally well with anakinra than canakinumab), as 5 out of 7 patients still received an on-demand regimen at the end of the study period. Both patients not responding to an on demand treatment with anakinra switched to a maintenance therapy with canakinumab with – according to the including physician – a good response.

The global incidence rate of adverse events in our study was slightly higher than in an Italian study (17.1 per 100 patient/years in our study vs. 8.4 in the Italian study) (Sota et al., 2018), but only already known side effects were described by the participating physicians (Table 2), with mainly-as anticipated-infectious complications (~11 per 100 patient/years). Most adverse events were considered to be mild and could be managed with minimal treatment modifications. No death, no neoplasm, no tuberculosis infection or reactivation, nor opportunistic infections were reported in our study. Our observations are comforting about the safety profile of IL1 inhibitors in HRFs and support the hypothesis that severe adverse events with IL1 inhibitors are preferentially related to the underlying diseases requiring IL1 inhibition and to the poor general clinical condition, rather than to an actual effect of IL-1 blockade (Sota et al., 2018).

We show a far better drug retention for canakinumab than for anakinra, whereas side effects seemed equally frequent in both groups. Our hypothesis is that the ease of treatment may be the most important point for treatment persistence in patients. It is worth noting, that during the scheduled switch from anakinra to canakinumab, none of the attending physicians pointed out that anakinra was not sufficiently effective to justify changing the medication. Similarly, patients with on-demand anakinra therapy with inadequate disease control switched directly to canakinumab–and not daily anakinra - maintenance therapy. These observations suggest that the ease of treatment is also a major argument guiding the choice of the drug for the prescribing physician.

The major flaw of our study is that due to the retrospective design of our study; we were not able to retrieve a standardized disease activity score and consequently we were not able to link the disease activity of the patients to their treatment regimens. However we consider that we can infer the control of disease activity indirectly by assuming that the adaptations of therapies decided by the investigating physician were made because of criteria related to the severity and the control of the disease. The observed highly variable treatment regimens, ranging from on demand treatment regimens to intensified dosage maintenance therapies, reflects in our opinion that in daily life the investigating physicians adapts drug dosages as closely as possible to disease activity. This is all the more true since our study took place before the French marketing authorization for IL1-inhibitors in HRFs, at a time when dosages had not yet been standardized by the SCP.

A second bias of our study concerns the heterogeneity of our sample, particularly concerning pathologies. However, this heterogeneity also highlighted that individual treatment needs are highly variable. Future studies should focus on identifying and refining the parameters underpinning the treat-to-target strategy practiced in HRFs.

Key Messages

- IL-1 inhibitors are a good treatment option for patients with a hereditary recurrent fever syndrome.
- The individual need of the dosage of IL-1 inhibitors to control the disease effectively seems highly variable, with about 45% of patients responding well to low dosages of IL-1 inhibitors.
- On-demand treatment with a short half-life IL-1 inhibitor may be a treatment option for some selected patients with a recurrent hereditary fever syndrome.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by French Ethic Committee (CCTIRS). Patients were enrolled after comprehensive information checking that they (or their legal guardian) were not opposed to the study and the storage of their personal data.

AUTHOR CONTRIBUTIONS

VH and SG-L were involved in the conception and design of the study. VH, SG-L, IK-P, AB, CG, GG, AC, AP, MH, and PP organized the data base. VH and MD analyzed the data. VH wrote the first draft of the manuscript. All authors contributed to the manuscript revision, read and approved the submitted version.

FUNDING

No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this article.

ACKNOWLEDGMENTS

The authors express their sincere thanks to François Hofer for the technical management of the JIR cohort and the help for preparing the data. The authors thank the Fondation Rhumatisme Suisse for hosting the JIR data base.

REFERENCES

- Abbara, S., Georgin-Lavialle, S., Stankovic Stojanovic, K., Bachmeyer, C., Senet, P., Buob, D., et al. (2017). Association of hidradenitis suppurativa and familial Mediterranean fever: a case series of 6 patients. *Jt. Bone Spine Rev. Rhum.* 84, 159–162. doi:10.1016/j.jbspin.2016.02.021
- Babaoglu, H., Varan, O., Kucuk, H., Atas, N., Satis, H., Salman, R., et al. (2019). On demand use of anakinra for attacks of familial Mediterranean fever (FMF). *Clin. Rheumatol.* 38, 577–581. doi:10.1007/s10067-018-4230-z
- Bodar, E. J., Kuijk, L. M., Drenth, J. P. H., van der Meer, J. W. M., Simon, A., and Frenkel, J. (2011). On-demand anakinra treatment is effective in mevalonate kinase deficiency. *Ann. Rheum. Dis.* 70, 2155–2158. doi:10.1136/ard.2011.149922
- Cavalli, G., and Dinarello, C. A. (2015). Treating rheumatological diseases and comorbidities with interleukin-1 blocking therapies. *Rheumatol. Oxf. Engl.* 54, 2134–2144. doi:10.1093/rheumatology/kev269
- De Benedetti, F., Gattorno, M., Anton, J., Ben-Chetrit, E., Frenkel, J., Hoffman, H. M., et al. (2018). Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N. Engl. J. Med. 378, 1908–1919. doi:10.1056/NEJMoa1706314
- Deshayes, S., Georgin-Lavialle, S., Hot, A., Durel, C-A., Hachulla, E., Rouanes, N., et al. (2018). Efficacy of continuous interleukin 1 blockade in mevalonate kinase deficiency: a multicenter retrospective study in 13 adult patients and literature review. J. Rheumatol. 45, 425–429. doi:10.3899/jrheum.170684
- European Medicines Agency (2018a). Available at: https://www.ema.europa.eu/en/ medicines/human/EPAR/kineret (Accessed April 19, 2020).
- European Medicines Agency (2018b). Ilaris: summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/001109/WC500031680.pdf (Accessed July 14, 2018).
- Gattorno, M., Hofer, M., Federici, S., Vanoni, F., Bovis, F., Aksentijevich, I., et al. (2019). Classification criteria for autoinflammatory recurrent fevers. Ann. Rheum. Dis. 78 (8), 1025–1032. doi:10.1136/annrheumdis-2019-215048
- Grimwood, C., Despert, V., Jeru, I., and Hentgen, V. (2015). On-demand treatment with anakinra: a treatment option for selected TRAPS patients. *Rheumatol. Oxf. Engl.* 54, 1749–1751. doi:10.1093/rheumatology/kev111
- Kone-Paut, I., Quartier, P., Fain, O., Grateau, G., Pillet, P., Le Blay, P., et al. (2017). Real-world experience and impact of canakinumab in cryopyrin-associated periodic syndrome: results from a French observational study. *Arthritis Care Res.* 69, 903–911. doi:10.1002/acr.23083

- Laskari, K., Boura, P., Dalekos, G. N., Garyfallos, A., Karokis, D., Pikazis, D., et al. (2017). Longterm beneficial effect of canakinumab in colchicine-resistant familial Mediterranean fever. J. Rheumatol. 44, 102–109. doi:10.3899/ jrheum.160518
- Meinzer, U., Quartier, P., Alexandra, J-F., Hentgen, V., Retornaz, F., and Koné-Paut, I. (2011). Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. *Semin. Arthritis Rheum.* 41, 265–271. doi:10.1016/j.semarthrit.2010.11.003
- Rossi-Semerano, L., Fautrel, B., Wendling, D., Hachulla, E., Galeotti, C., Semerano, L., et al. (2015). Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J. Rare Dis. 10, 19. doi:10.1186/ s13023-015-0228-7
- Sota, J., Vitale, A., Insalaco, A., Sfriso, P., Lopalco, G., Emmi, G., et al. (2018). Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. *Clin. Rheumatol.* 37 (8), 2233–2240. doi:10.1007/s10067-018-4119-x
- Stankovic Stojanovic, K., Delmas, Y., Torres, P. U., Peltier, J., Pelle, G., Jéru, I., et al. (2012). Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. *Nephrol. Dial. Transplant.* 27, 1898–1901. doi:10.1093/ndt/ gfr528

Conflict of Interest: VH, IK, GG, MH, and SG-L received personal fees and non-financial support from Novartis and SOBI; CG and AB received non-financial support from Novartis; AP received non-financial support from SOBI.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hentgen, Koné-paut, Belot, Galeotti, Grateau, Carbasse, Pagnier, Pillet, Delord, Hofer and Georgin-Lavialle. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.